Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 3
1991 1
1992 1
1993 1
2007 1
2014 2
2015 1
2016 1
2020 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Antigen-detecting rapid tests or real-time PCR, what test to use and why?
Revollo Barriga B, Llibre Codina JM. Revollo Barriga B, et al. Among authors: llibre codina jm. Enferm Infecc Microbiol Clin (Engl Ed). 2021 Dec;39(10):531-532. doi: 10.1016/j.eimce.2021.09.008. Epub 2021 Sep 16. Enferm Infecc Microbiol Clin (Engl Ed). 2021. PMID: 34551889 Free PMC article. No abstract available.
[Antigen-detecting rapid tests or real-time PCR, what test to use and why?].
Revollo Barriga B, Llibre Codina JM. Revollo Barriga B, et al. Among authors: llibre codina jm. Enferm Infecc Microbiol Clin. 2021 Dec;39(10):531-532. doi: 10.1016/j.eimc.2021.06.001. Epub 2021 Jun 12. Enferm Infecc Microbiol Clin. 2021. PMID: 34149139 Free PMC article. Spanish. No abstract available.
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
Dickinson L, Gurjar R, Stöhr W, Bonora S, Owen A, D'Avolio A, Cursley A, Molina JM, Fäetkenheuer G, Vandekerckhove L, Di Perri G, Pozniak A, Richert L, Raffi F, Boffito M; NEAT001/ANRS143 Study Group. Dickinson L, et al. J Antimicrob Chemother. 2020 Mar 1;75(3):628-639. doi: 10.1093/jac/dkz479. J Antimicrob Chemother. 2020. PMID: 31754703 Clinical Trial.
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group. Lambert-Niclot S, et al. J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. J Antimicrob Chemother. 2016. PMID: 26702926 Free article. Clinical Trial.
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Raffi F, et al. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4. Lancet. 2014. PMID: 25103176 Clinical Trial.
[Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients].
Llibre-Codina JM, Casado-Gómez MA, Sánchez-de la Rosa R, Pérez-Elías MJ, Santos-González J, Miralles-Alvarez C, Martínez-Chamorro E, Domingo-Pedrol P, Alvarez-García ML, Moreno-Guillén S. Llibre-Codina JM, et al. Enferm Infecc Microbiol Clin. 2007 Feb;25(2):98-107. doi: 10.1157/13098570. Enferm Infecc Microbiol Clin. 2007. PMID: 17288907 Spanish.
13 results